TickerTalks
Browse all tickers →
TickerTalks›$PRAX
PRPRAX

Praxis Precision Medicines, Inc.

$PRAX·$10B·Biotechnology·Healthcare
$350.30+1.6%YTD+6.7%1Y+679.5%
Mentions · last 7 days
2026-08-22: 2 posts2026-08-23: 3 posts32-15%
Price updated 6h ago·X counts updated 8d ago
PRPRAX
$PRAXPraxis Precision Medicines, Inc.
$350.30+1.61%32 posts-15%
AI analysisFundamentalsVoices on X
Loading…

AI verdict & sentimentAI analysisGenerated by AI from underlying data

Top X posts

Today's AI verdict on what's driving $PRAX, plus how loud the X conversation is and which way it's leaning.

AI analysis

TickerTalks’ read on the fundamentals and what’s driving the move.

Hinges on a big eventEvent coming upAI verdict · as of 2026-08-30

A known event soon (earnings, a ruling, etc.) will likely decide the next move.

Praxis +650% TTM, Truist $616 PT — ulixacaltamide PDUFA Jan 27, relutrigine PDUFA Dec 27, no adcoms required.

Praxis Precision Medicines is a $10B CNS-oncology biotech. +650% TTM with two dated PDUFA catalysts within 12 months plus $1.4B cash runway into 2028.

How it reads:

  • Fundamentals are pre-revenue: Q1 revenue $0M — the entire equity is the two-drug PDUFA setup.
  • Margins reflect burn: -25.3% ROIC, -5.3% FCF yield — heavy R&D but well-funded.
  • Valuation is pipeline-priced: -22.5x PE (unprofitable), PS 0 (no revenue), -13.7x EV/EBITDA — priced on the PDUFA setup, not P&L.
  • Position is stretched: 87th percentile 52w, 3.1% above 50-day, 13.5% above 200-day on 72% baseline volume — quiet accumulation into the catalysts.
  • The specific catalysts: ulixacaltamide (ET, PDUFA Jan 29 '27) plus relutrigine (SCN2A/8A DEEs, PDUFA Dec 27) — mid-cycle reviews showed no meaningful regulatory issues and no adcom meetings required.
  • Truist maintains Buy at $616 PT — targets ~79% above current $345.
  • Q2 cash of $1.4B provides runway into 2028 — no dilution risk near-term.
  • July 2 dismissed EY as auditor (EY had clean FY2024 and FY2025 opinions with no adverse issues) — worth flagging even though EY confirmed no issues, auditor changes are always worth naming.
  • Insider signal is silent: zero transactions in 90-day window — no distribution or accumulation.

The Dec 27 relutrigine PDUFA is the first test — a specific FDA approval plus reiterated Q1 ulixacaltamide readout keeps the setup; a CRL on either drug drops to $220 support and the platform thesis lags.

Agrees with X sentimentAgree — the bullish anchors ($1.4B cash providing runway into 2028 with two potential launches prepping, Truist maintains Buy at $616 PT, mid-cycle reviews for ulixacaltamide/relutrigine showed no meaningful regulatory issues and no adcom meetings required, PDUFA Jan 29 '27 and Dec 27, Praxis on major-catalyst list) map to real signals; the honest add is the July 2 EY-dismissal-as-auditor (with EY confirmed no adverse opinions) is worth naming — auditor changes always are.

What to watch: Dec 27 relutrigine PDUFA — a specific FDA approval plus reiterated Q1 ulixacaltamide readout keeps the setup; a CRL on either drug drops to $220 support.

On the calendar: 2026-11-09 — Q3 earnings; Dec 27 relutrigine PDUFA

X sentiment

What the X crowd is saying right now — descriptive, summarised from the day’s posts.

Bullish sentiment5 posts analyzed · as of 2026-08-13

Praxis Precision Medicines posts Q2 with $1.4B cash providing runway into 2028 as it preps two potential launches. Truist maintains Buy at $616 PT after the mid-cycle reviews for ulixacaltamide (ET, PDUFA Jan 29 '27) and relutrigine (SCN2A/8A DEEs, PDUFA Dec 27) showed no meaningful regulatory issues and no adcom meetings required.

Read the AI verdict + X sentiment for $PRAX

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • X crowd read with bullish/bearish call + post volume
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Develops sodium and potassium channel modulators for epilepsy and neurological disorders in clinical trials.

Industry overviewAI analysisGenerated by AI from underlying data

Where Biotechnology sits in its cycle right now — and what that implies for $PRAX.

Biotechnology · Healthcare

GLP-1 oral formulation competition — emerging clinical data from pipeline challengers — is the central bifurcation: platform holders (LLY, NVO) defend on efficacy breadth while precision oncology names decouple entirely. FDA catalyst cadence over the next 60 days sets the near-term tone.

What this means for $PRAX

Partial — fee-based midstream revenue has limited direct commodity price exposure but volume ties to upstream production activity.

Top industry ETF

$IBBiShares Biotechnology ETF
+12.1%YTD
+48.9%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
-22.5How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
-25.3%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
0.0%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
-5.3%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
0.0Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
-43.0%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
0.0%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
0.0Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q2 2026Aug 6, 2026$-2.87$-3.67+21.8%
Q1 2026May 7, 2026$-3.20$-3.58+10.6%
Q4 2025Feb 19, 2026$-3.50$-3.13-12.0%
Q3 2025Nov 5, 2025$-3.36$-3.45+2.6%
Next earningsMon, Nov 9·consensus EPS $-3.65

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$0———$-3.20$-86.1M
Q4 FY25$0-100.0%——$-3.52$-77.3M
Q3 FY25$0-100.0%——$-3.36$-64.7M
Q2 FY25$0-100.0%——$-3.31$-54.8M

Forward consensus

5-year forecast · up to 17 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$2.4M$1.1M – $3.6M-$15.27-$16.51 – -$14.0714
FY27$342.3M$171.4M – $441.1M-$10.40-$20.20 – -$4.7614
FY28$1.1B$515.7M – $2.1B$7.03-$11.46 – $28.0317
FY29$2.2B$997.3M – $4.1B$29.69$8.51 – $62.5914
FY30$3.5B$1.6B – $6.5B$52.12$14.94 – $109.858

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.0.9×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.88%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.+4.4%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.+15.0%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatLow float · 26.1M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today1.3% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β2.785-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

SellJun 24Jill DesimoneDirector11.6K sh$3.6M
+ 15 other (13 awards · 1 gift · 1 exempt) in window

See when $PRAX insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

8-KPress release / Reg FDAug 68-K — Item 2.02: Earnings release · Item 7.01: Press release / Reg FD
AI summary

PRAXIS PRECISION MEDICINES, INC. (PRAX) reported Q2 2026 financial results on 2026-08-06, reporting financial results details in attached press release. Additional items: Item 7.01. Quarterly earnings are a material disclosure; investors should review the full press release for segment details and management commentary.

8-KMaterial eventJul 28-K — Item 4.01
AI summary

Praxis Precision Medicines dismissed Ernst and Young as independent auditor effective June 29, 2026; EY's clean opinions for FY2024 and FY2025 contained no adverse opinions, qualifications, or disagreements. No replacement auditor was named in the filing. Notable auditor change requiring investor attention; clean prior track record reduces immediate concern.

8-KShareholder voteJun 128-K — Item 5.07: Shareholder vote
AI summary

Praxis Precision Medicines held its 2026 Annual Meeting on June 10, 2026. Shareholders elected three Class III director nominees — Gregory Norden, Marcio Souza, and William Young — each to serve through 2029; ratified Ernst & Young LLP as independent auditor; and approved the advisory say-on-pay vote on executive compensation. Routine annual governance with no material business changes or contested outcomes.

8-KPress release / Reg FDMay 78-K — Item 2.02: Earnings release · Item 7.01: Press release / Reg FD
AI summary

PRAX reported period ending 2026-05-13 financial results (8-K Item 2.02). Investors should review the full earnings press release and any management guidance for forward outlook.

+ 17 other (7 13Gs · 6 routine 8-Ks · 2 10-Qs · 2 proxys) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Receives Consensus Rating of “Buy” from Brokeragesdefenseworld.net·5d agoPraxis Precision Medicines (NASDAQ:PRAX) Hits New 1-Year High – What’s Next?defenseworld.net·14d ago9,840 Shares in Praxis Precision Medicines, Inc. $PRAX Purchased by Handelsbanken Fonder ABdefenseworld.net·16d ago4 Biotech Stocks With Major Second-Half Pipeline Catalysts This Yearzacks.com·21d agoPraxis: Commercial Launch Could Smash Expectations (Video)seekingalpha.com·24d ago

In themes

Explore the broader themes this ticker is being talked about under.

Best Performers

More in Biotechnology

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$MRNA$ALT$AURA$IOVA$NWBO$SLS$AMLX$ABCL
Voices on X · top 3 · last 7 days

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport